Alzheimer’s disease (AD) is one of the major age related neurodegenerative diseases whose pathology arises due to the presence of two distinct protein aggregates, viz., amyloid-β plaques in extracellular matrix and tau neurofibrillary tangles in neurons. Multiple factors play a role in AD pathology, which includes familial mutations, oxidative stress, and post-translational modifications. Melatonin is an endocrine hormone, secreted during darkness, derived from tryptophan, and produced mainly by the pineal gland. It is an amphipathic molecule, which makes it suitable to cross not only blood-brain barrier, but also to enter several other subcellular compartments like mitochondria and endoplasmic reticulum. In this context, the neuroprotective effect of melatonin may be attributed to its role as an antioxidant. Melatonin’s pleiotropic function as an antioxidant and neuroprotective agent has been widely studied. However, its direct effect on the aggregation of tau and amyloid-β needs to be explored. Furthermore, an important aspect of its function is its ability to regulate the process of phosphorylation of tau by affecting the function of kinases and phosphatases. In this review, we are focusing on the pleiotropic function of melatonin on the aspect of its neuroprotective function in tau pathology, which includes antioxidant function, regulation of enzymes, including kinases and enzymes involved in free radical scavenging and mitochondrial protection.
Mondragón-RodríguezS, PerryG, ZhuX, BoehmJ (2012) Amyloid beta and tau proteins as therapeutic targets for Alzheimer’s disease treatment: Rethinking the current strategy. Int J Alzheimers Dis2012, 630182.
ClaustratB, BrunJ, ChazotG (2005) The basic physiology and pathophysiology of melatonin. Sleep Med Rev9, 11–24.
6.
HardelandR, PoeggelerB (2008) Melatonin beyond its classical functions. Open Physiol J1, 1–23.
7.
KimMJ, KimHK, KimBS, YimSV (2004) Melatonin increases cell proliferation in the dentate gyrus of maternally separated rats. J Pineal Res37, 193–197.
8.
TanDX, ReiterRJ, ManchesterLC, YanMT, El-SawiM, SainzRM, MayoJC, KohenR, AllegraM, HardelandR (2002) Chemical and physical properties and potential mechanisms: Melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem2, 181–197.
9.
WangJZ, WangZF (2006) Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin27, 41–49.
10.
ReiterRJ (1995) Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J9, 526–533.
11.
WangX (2009) The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther15, 345–357.
12.
Tomás-ZapicoC, Coto-MontesA (2005) A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res39, 99–104.
13.
ZhouJN, LiuRY, KamphorstW, HofmanMA, SwaabDF (2003) Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res35, 125–130.
14.
LinL, HuangQX, YangSS, ChuJ, WangJZ, TianQ (2013) Melatonin in Alzheimer’s disease. Int J Mol Sci14, 14575–14593.
15.
LingZQ, TianQ, WangL, FuZQ, WangXC, WangQ, WangJZ (2009) Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin. J Alzheimers Dis16, 287–300.
16.
QuinnJ, KulhanekD, NowlinJ, JonesR, PraticòD, RokachJ, StackmanR (2005) Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials. Brain Res1037, 209–213.
17.
MatsubaraE, Bryant-ThomasT, Pacheco QuintoJ, HenryTL, PoeggelerB, HerbertD, Cruz-SanchezF, ChyanYJ, SmithMA, PerryG, ShojiM, AbeK, LeoneA, Grundke-IkbalI, WilsonGL, GhisoJ, WilliamsC, RefoloLM, PappollaMA, ChainDG, NeriaE (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem85, 1101–1108.
18.
KlongpanichapakS, Phansuwan-PujitoP, EbadiM, GovitrapongP (2008) Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK–N–SH cells. Neurosci Lett436, 309–313.
19.
Sae-UngK, UédaK, GovitrapongP, Phansuwan-PujitoP (2012) Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J Pineal Res52, 128–137.
20.
OnoK, MochizukiH, IkedaT, NihiraT, TakasakiJ, TeplowDB, YamadaM (2012) Effect of melatonin on α-synuclein self-assembly and cytotoxicity. Neurobiol Aging33, 2172–2185.
21.
CuzzocreaS, ZingarelliB, GiladE, HakeP, SalzmanAL, SzabóC (1997) Protective effect of melatonin in carrageenan-induced models of local inflammation: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res23, 106–116.
22.
SrinivasanV, Pandi-PerumalSR, MaestroniGJ, EsquifinoAI, HardelandR, CardinaliDP (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res7, 293–318.
HardelandR, PoeggelerB (2007) Actions of melatonin, its structural and functional analogs in the central nervous system and the significance of metabolism. Cent Nerv Syst Agents Med Chem7, 289–303.
25.
GuptaD, ReiterRJ (1986) Human development and the pineal gland. pp. The Pineal Gland During Development: From Fetus To Adult, DGupta, RJReiter (eds). Croom Helm, London, pp. 117–133.
26.
RosengartenH, MellerE, FriedhoffA (1972) In vitro enzymatic formation of melatonin by human erythrocytes. Res Commun Chem Pathol Pharmacol4, 457–465.
27.
HardelandR, FuhrbergB (1996) Ubiquitous melatonin–presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol2, 25–45.
28.
ReiterRJ (1991) Pineal melatonin: Cell biology of its synthesis and of itshysiological interactions. Endocr Rev12, 151–180.
29.
ReppertSM, WeaverDR, EbisawaT (1994) Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron13, 1177–1185.
30.
HardelandR, ReiterRJ, PoeggelerB, TanDX (1993)The significance of the metabolism of the neurohormone melatonin: Antioxidativerotection and formation of bioactive substances. Neurosci Biobehav Rev17, 347–357.
31.
RodriguezC, MayoJC, SainzRM, AntolinI, HerreraF, MartinV, ReiterRJ (2004) Regulation of antioxidant enzymes: A significant role for melatonin. J Pineal Res36, 1–9.
32.
PeschkeE, FreseT, ChankiewitzE, PeschkeD, PreissU, SchneyerU, SpessertR, MühlbauerE (2006) Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res40, 135–143.
33.
PeschkeE, MühlbauerE, MusshoffU, CsernusVJ, ChankiewitzE, PeschkeD (2002) Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res33, 63–71.
34.
PeschkeE, FauteckJD, MusshoffU, SchmidtF, BeckmannA, PeschkeD (2000) Evidence for a melatonin receptor within pancreatic islets of neonate rats: Functional, autoradiographic, and molecular investigations. J Pineal Res28, 156–164.
35.
EspinoJ, ParienteJA, RodríguezAB (2011) Role of melatonin on diabetes-related metabolic disorders. World J Diabetes2, 82–91.
JouMJ, PengTI, ReiterRJ, JouSB, WuHY, WenST (2004) Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res37, 55–70.
TanDX, ManchesterLC, ReiterRJ, PlummerBF, LimsonJ, WeintraubST, QiW (2000) Melatonin directly scavenges hydrogen peroxide: A potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med29, 1177–1185.
47.
Witt-EnderbyPA, BennettJ, JarzynkaMJ, FirestineS, MelanMA (2003) Melatonin receptors and their regulation: Biochemical and structural mechanisms. Life Sci72, 2183–2198.
48.
CardinaliD, RosensteinR, GolombekD, ChuluyanH, KanterewiczB, Del ZarM, VacasM (1991) Melatonin binding sites in brain: Single or multile. Adv Pineal Res5, 159–165.
49.
ReppertSM (1997) Melatonin receptors: Molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms12, 528–531.
50.
LeónJ, EscamesG, RodríguezMI, LópezLC, TapiasV, EntrenaA, CamachoE, CarriónMD, GalloMA, EspinosaA, TanDX, ReiterRJ, Acuña-CastroviejoD (2006) Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem98, 2023–2033.
51.
Acuña-CastroviejoD, EscamesG, LópezLC, HitosAB, LeónJ (2005) Melatonin and nitric oxide: Two required antagonists for mitochondrial homeostasis. Endocrine27, 159–168.
52.
UrataY, HonmaS, GotoS, TodorokiS, IidaT, ChoS, HonmaK, KondoT (1999) Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med27, 838–847.
MayoJC, SainzRM, AntolinI, HerreraF, MartinV, RodriguezC (2002) Melatonin regulation of antioxidant enzyme gene expression. Life Sci59, 1706–1713.
55.
PablosMI, AgapitoMT, GutierrezR, RecioJM, ReiterRJ, Barlow-WaldenL, Acuña-CastroviejoD, Menendez-PelaezA (1995) Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J Pineal Res19, 111–115.
ChristenY (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr71621S–629S.
61.
MandelkowE-M, MandelkowE (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med2, a006247.
62.
GiacobiniE, GoldG (2013) Alzheimer disease therapy—moving from amyloid-β to tau. Nat Rev Neurol9, 677–686.
63.
PappollaMA, SosM, OmarRA, BickRJ, Hickson-BickDL, ReiterRJ, EfthimiopoulosS, RobakisNK (1997) Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci17, 1683–1690.
64.
PappollaM, BoznerP, SotoC, ShaoH, RobakisNK, ZagorskiM, FrangioneB, GhisoJ (1998) Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem273, 7185–7188.
65.
SkribanekZ, BaláspiriL, MákM (2001) Interaction between synthetic amyloid-beta-peptide (1–40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom36, 1226–1229.
IqbalK, Grundke-IqbalI (2005) Metabolic/signal transduction hypothesis of Alzheimer’s disease and other tauopathies. Acta Neuropathol109, 25–31.
68.
BrandtR, LeschikJ (2004) Functional interactions of tau and their relevance for Alzheimer’s disease. Curr Alzheimer Res1, 255–269.
69.
FerrerI, Gomez-IslaT, PuigB, FreixesM, RibéE, DalfóE, AvilaJ (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Curr Alzheimer Res2, 3–18.
70.
HoppeJB, FrozzaRL, HornAP, ComiranRA, BernardiA, CamposMM, BattastiniAM, SalbegoC (2010) Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: Involvement of GSK-3beta, tau and neuroinflammation. J Pineal Res48, 230–238.
71.
ZempelH, ThiesE, MandelkowE, MandelkowEM (2010) Abeta oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci30, 11938–11950.
72.
WangJZ, WuQ, SmithA, Grundke-IqbalI, IqbalK (1998) Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett436, 28–34.
73.
PlanelE, YasutakeK, FujitaSC, IshiguroK (2001) Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem276, 34298–34306.
74.
AliT, KimMO (2015) Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus. J Pineal Res59, 47–59.
75.
PengCX, HuJ, LiuD, HongXP, WuYY, ZhuLQ, WangJZ (2013) Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer’s animal model. Neurobiol Aging34, 1555–1563.
76.
WangDL, LingZQ, CaoFY, ZhuLQ, WangJZ (2004) Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res37, 11–16.
77.
YinJ, LiuYH, XuYF, ZhangYJ, ChenJG, ShuBH, WangJZ (2006) Melatonin arrests peroxynitrite-induced tau hyperphosphorylation and the overactivation of protein kinases in rat brain. J Pineal Res41, 124–129.
78.
LiuSJ, WangJZ (2002) Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin23, 183–187.
79.
DengYQ, XuGG, DuanP, ZhangQ, WangJZ (2005) Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin26, 519–526.
80.
AlviraD, TajesM, VerdaguerE, Acuña-CastroviejoD, FolchJ, CaminsA, PallasM (2006) Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson’s disease. J Pineal Res40, 251–258.
81.
WangS, ZhuL, ShiH, ZhengH, TianQ, WangQ, LiuR, WangJZ (2007) Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. Neurochem Res32,, 1329–1335.
82.
WangXC, ZhangYC, ChatterjieN, Grundke-IqbalI, IqbalK, WangJZ (2008) Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells. Neurochem Res33, 1138–1144.
83.
SunL, LiuSY, ZhouXW, WangXC, LiuR, WangQ, WangJZ (2003) Inhibition of protein phosphatase 2A-and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience118, 1175–1182.
84.
LiuF, Grundke-IqbalI, IqbalK, GongCX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci22, 1942–1950.
85.
KinsS, CrameriA, EvansDR, HemmingsBA, NitschRM, GotzJ (2001) Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem276,, 38193–38200.
86.
GongCX, LidskyT, WegielJ, ZuckL, Grundke-IqbalI, IqbalK (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer’s disease. J Biol Chem275, 5535–5544.
87.
LiXC, WangZF, ZhangJX, WangQ, WangJZ (2005) Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol510, 25–30.
88.
TanDX, ManchesterLC, ReiterRJ, QiWB, KarbownikM, CalvoJR (2000) Significance of melatonin in antioxidative defense system: Reactions and products. Biol Signals Recept9, 137–159.
89.
BradtBM, KolbWP, CooperNR (1998) Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med188, 431–438.
90.
McGeerP, AkiyamaH, ItagakiS, McGeerE (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett107, 341–346.
91.
RogersJ, CooperNR, WebsterS, SchultzJ, McGeerPL, StyrenSD, CivinWH, BrachovaL, BradtB, WardP (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A89,, 10016–10020.
ItagakiS, AkiyamaH, SaitoH, McGeerPL (1994) Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer’s disease. Brain Res645, 78–84.
94.
WebsterS, LueLF, BrachovaL, TennerAJ, McGeerPL, TeraiK, WalkerDG, BradtB, CooperNR, RogersJ (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease. Neurobiol Aging18, 415–421.
95.
BiliciD, AkpinarE, KiziltunçA (2002) Protective effect of melatonin in carrageenan-induced acute local inflammation. Pharmacol Res46, 133–139.
96.
PozoD, ReiterRJ, CalvoJR, GuerreroJM (1997) Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem65, 430–442.
97.
CostantinoG, CuzzocreaS, MazzonE, CaputiAP (1998) Protective effects of melatonin in zymosan-activated plasma-induced paw inflammation. Eur J Pharmacol363, 57–63.
98.
DavisKL, MohsRC, MarinD, PurohitDP, PerlDP, LantzM, AustinG, HaroutunianV (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA281, 1401–1406.
99.
Terry AVJr, BuccafuscoJJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther306, 821–827.
100.
FengZ, ChangY, ChengY, ZhangBL, QuZW, QinC, ZhangJT (2004) Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease. J Pineal Res37, 129–136.
101.
BanksWA (2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol9, S3.
102.
AbbottNJ, PatabendigeAA, DolmanDE, YusofSR, BegleyDJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis37, 13–25.
103.
YuH, DicksonEJ, JungSR, KohDS, HilleB (2016) High membrane permeability for melatonin. J Gen Physiol147, 63–76.
104.
Antón-TayF, DíazJL, Fernández-GuardiolaA (1971) On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci10, 841–850.
105.
PenichetML, KangYS, PardridgeWM, MorrisonSL, ShinSU (1999) An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain. J Immunol163, 4421–4426.
